Evaluation of the Cerebroprotective Properties of Ademol-gel in the Analysis of Specific Indicators in the Open Field Test
-
Published:2023-06-30
Issue:2
Volume:16
Page:1219-1227
-
ISSN:2456-2610
-
Container-title:Biomedical and Pharmacology Journal
-
language:en
-
Short-container-title:Biomed. Pharmacol. J.
Author:
Semenenko Sviatoslav1ORCID, Semenenko Igor2ORCID, Burlaka Bogdan3ORCID, Samura Iryna4ORCID, Bukhtiyarova Nina5ORCID, Ryzhenko Viktor6ORCID, Khromylova Olga7ORCID
Affiliation:
1. 1 Department of Clinical Pharmacy and Clinical Pharmacology, National Pirogov Memorial Medical University, Ukraine. Orcid ID: 0000-0003-3148-2199 2. 2 Department of Therapeutic Disciplines and Family Medicine, National Pirogov Memorial Medical University, Vinnitsa, Ukraine. Orcid ID: 0000-0002-3611-5796 3. 3 Department of Medicines Technology, Zaporizhzhia State Medical University, Ukraine. Orcid ID: 0000-0003-4539-7331 4. 4Department of Pharmacology and Medical Formulation with the Course of Normal Physiology, Zaporizhzhia State Medical University. Ukraine. 5. 5Department of Clinical Laboratory Diagnostics, Zaporizhzhia State Medical University, Ukraine. 6. 6Department of Medical and Pharmaceutical Informatics and Advanced Technologies, Zaporizhzhia State Medical University, Ukraine. 7. 7Department of Pharmaceutical, Organic and Bioorganic Chemistry, Zaporizhzhia State Medical University, Ukraine.
Abstract
Experimental subarachnoid hemorrhage (SAH) modeling in rats led to a significant, by 3 times, decrease in the total activity of animals, a decrease in the distance traveled by 2 times, a significant increase in inactivity when moving from the dark field to the illuminated part by 2 times, indicating a decrease in locomotor and search activity. SAH did not affect the number of unsupported rearing, but led to an increase in supported rearing against the wall, and a decrease in the number of short grooming acts against the background of an unchanged amount of long grooming. This behavior also testified to increased anxiety, excitability, irritability of animals, discomfort, and depression. The intranasal introduction of Ademol-gel at a dose of 2 mg/kg (a developed original intranasal form) to animals with SAH contributed to the positive emotional status and behavior of rats in the open field test, as evidenced by a decrease in anxiety, aggressiveness, and depressive behavior against the background of increased comfort and empathy in animals. Against the background of the intranasal introduction of Ademol-gel, the processes of restoring general motor and exploratory activity in animals after SAH were also accelerated. Nimodipine (30 μg/kg) was inferior to Ademol in terms of the degree of influence on the studied parameters of animal behavior. The results are an experimental justification for further study of a new dosage form – Ademol intranasal gel.
Publisher
Oriental Scientific Publishing Company
Reference19 articles.
1. 1. Maas AIR, Menon DK, Manley GT, Abrams M, Åkerlund C, Andelic N, Aries M, Andelic N, Aries M, Bashford T, Bell MJ, Bodien YeG, Brett BL, Büki A, Chesnut RM, Citerio G, Clark D, Clasby B, Cooper DJ, Czeiter E, Czosnyka M, Dams-O’Connor K, Keyser VD, Diaz-Arrastia R, Ercole A, Essen TA, Falvey E, Ferguson AR, Figaji A, Fitzgerald M, Foreman B, Gantner D, Gao G, Giacino J, Gravesteijn B, Guiza F, Gupta D, Gurnell M, Haagsma JA, Hammond FM, Hawryluk G, Hutchinson P, Jagt M, Jain S, Jain S, Jiang J, Kent H, Kolias A, Kompanje EJO, Lecky F, Lingsma HF, Maegele M, Majdan M, Markowitz A, McCrea M, Meyfroidt G, Mikolić A, Mondello S, Mukherjee P, Nelson D, Nelson LD, Newcombe V, Okonkwo D, Orešič M, Peul W, Pisică D, Polinder S, Ponsford J, Puybasset L, Raj R, Robba C, Røe R, Rosand J, Schueler P, Sharp DJ, Smielewski P, Stein MB, Steinbüchel N, Stewart W, Steyerberg EW, Stocchetti N, Temkin N, Tenovuo O, Theadom A, Thomas I, Espin AT, Turgeon AF, Unterberg A, Praag D, Veen E, Verheyden J, Vyvere TV, Wang KKW, Wiegers EJA, Williams WH, Wilson L, Wisniewski SR, Younsi A, Yue JK, Yuh EL, Zeiler FA, Zeldovich M, Zemek R. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022;21(11):1004-1060. doi: 10.1016/S1474-4422(22)00309-X. 2. 2. Semenenko SI, Khrebtiі Н, Semenenko AI. Cerebroprotective properties of Ademol in traumatic brain injury. Bukovinian Medical Herald. 2020;94(2): 159-166. http://e-bmv.bsmu.edu.ua/article/view/ 2413-0737.XXIV.2.94.2020.58/212691 3. 3. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clinical and Experimental Hypertension. 2008; 30(8): 744-766. doi: 10.1080/10641960802580232. 4. 4. Changkai H,· Quanlei Li, Hao Zhao, Weihan W, Bangyue W, Xiaopeng C, Jian Li, Wen R, Xinyu Y. Nimodipine attenuates early brain injury by protecting the lymphatic system after subarachnoid hemorrhage in mice. Neurochemical Research. 2022;47(3):701-712. doi:10.1007/s11064-021-03478-9. 5. 5. Zhaboiedova NV, Zagorii GV, Khodakovskyi AA. Screening cerebroprotective properties of industrial designs ampoule solution 1-adamantiloxy-3-morfolino-2-propanol hydrochloride (“Ademol”) on the model of acute cerebrovascular accident by hemorrhagic type. Reports of Morphology. 2016;22(1):83-86. https://morphology-journal.com/index.php/journal/article/view/234.
|
|